San Francisco—Bristol Myers Squibb is already aiming to launch more than 10 new medicines by 2030. | Bristol Myers Squibb is already aiming to launch more than 10 new medicines by 2030. But to hear CEO Chris Boerner, Ph.D., tell it, “business development remains a top priority” for the company’s capital allocation strategy heading into 2026.
START SELLING WITH BigBCC TODAY
Start your free trial with BigBCC today.
BLOG | Business
JPM26: Bristol Myers CEO to ‘cast a broad net’ as business development remains a top priority






